Gefitinib

Indications & Dose:

Treatment of locally advanced or metastatic non-small cell lung cancer with activating mutations of epidermal growth factor receptor

BY MOUTH

Adult: 250 mg once daily.

Contraindications:

Side Effects:

Common or very common Acne . anorexia . asthenia . blepharitis . conjunctivitis . diarrhoea . dry eye . dry mouth . dry skin . epistaxis . haematuria . interstitial lung disease—discontinue if confirmed . nail disorder . proteinuria . pruritus . pyrexia . rash . skin reactions Uncommon Corneal erosion . pancreatitis Rare Hepatitis . toxic epidermal necrolysis Frequency not known Alopecia . bone-marrow suppression . hyperuricaemia . nausea . oral mucositis . thromboembolism . tumour lysis syndrome . vomiting

CONCEPTION AND CONTRACEPTION

Contraceptive advice

BREAST FEEDING

Discontinue breast-feeding.

HEPATIC IMPAIRMENT

Manufacturer advises caution in moderate to severe impairment due to cirrhosis.

RENAL IMPAIRMENT

Manufacturer advises caution if creatinine clearance less than 20 mL/minute.

Cautions:

Precautions:

Interaction:

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: